Akebia Therapeutics, Inc.
(NASDAQ:AKBA)
$1.13
-0.04 (-3.42%)
Open: 12:57 PM
AKBA Stock Price Graph
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- YTD
- All
AKBA Stock Price Today
Akebia Therapeutics, Inc. (AKBA) stock declined over -3.42% intraday to trade at $1.13 a share on NASDAQ. The stock opened with a loss of -28.21% at $0.84 and touched an intraday high of $0.85, falling -3.42% against the last close of $1.17. The Akebia Therapeutics, Inc. in stock market went to a low of $0.80 during the session.
AKBA Stock Snapshot
$1.17
Prev. Close
212.88 Million
Market Cap
$0.80
Day Low
$0.84
Open
N/A
Number of Shares
$0.85
Day High
N/A
P/E ratio
-0.33
EPS (TTM)
0.25
Cash Flow per Share
N/A
Free Float in %
-0.21
Book Value
869618.00
Volume
AKBA Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|
Contact Details
Company Information
EmployeesN/A
Beta0.77
Sales or Revenue$194.21 Million
5Y Sales Change14.78%
Fiscal Year EndsDec. 2022
SectorHealthcare
IndustryBiotechnology
About Company
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Peers
Frequently Asked Questions
What is the current Akebia Therapeutics, Inc. (AKBA) stock price?
Akebia Therapeutics, Inc. (NASDAQ: AKBA) stock price is $1.13 in the last trading session. During the trading session, AKBA stock reached the peak price of $0.85 while $0.80 was the lowest point it dropped to. The percentage change in AKBA stock occurred in the recent session was -3.42% while the dollar amount for the price change in AKBA stock was -$0.04.
AKBA's industry and sector of operation?
The NASDAQ listed AKBA is part of Biotechnology industry that operates in the broader Healthcare sector. Akebia Therapeutics, Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Who are the executives of AKBA?
Mr. John P. Butler MBA
Chief Executive Officer, Pres & Director
Ms. Nicole R. Hadas J.D.
Senior Vice President, Chief Legal Officer & Sec.
Mr. David A. Spellman
Senior Vice President, Chief Financial Officer & Treasurer
Ms. Violetta Cotreau
Senior Vice President, Chief Accounting Officer & Principal Accounting Officer
How AKBA did perform over past 52-week?
AKBA's closing price is 2.86% higher than its 52-week low of $0.243 where as its distance from 52-week high of $1.84 is -0.23%.
How many employees does AKBA have?
Number of AKBA employees currently stands at N/A. AKBA operates from 245 First Street, Cambridge, MA 02142, US.
Link for AKBA official website?
Official Website of AKBA is: https://www.akebia.com
How do I contact AKBA?
AKBA could be contacted at phone #617 871 2098 and can also be accessed through its website. AKBA operates from 245 First Street, Cambridge, MA 02142, US.
How many shares of AKBA are traded daily?
AKBA stock volume for the day was 869618.00 shares. The average number of AKBA shares traded daily for last 3 months was 1.31 Million.
What is the market cap of AKBA currently?
The market value of AKBA currently stands at $212.88 Million with its latest stock price at $1.13 and N/A of its shares outstanding.